Streetbeat News

SDZNY

Sandoz Group AG

Industry

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

Open

44.92

Mkt cap

20B

Volume

3.3K

High

45.50

P/E Ratio

-2275.00

52-wk high

46.80

Low

44.91

Div yield

0.01

52-wk low

27.79

The article compares Sandoz Group AG Sponsored ADR (SDZNY) and Zoetis (ZTS) to determine which stock offers better value for investors interested in the Medical - Drugs sector.

Portfolio Pulse from

November 18, 2024 | 6:00 pm

Agomab Therapeutics NV has appointed Colin Bond, former CFO of Sandoz, to its Board of Directors as a non-executive Director and Chairman of the Audit Committee. Colin Bond brings over three decades of finance experience, including fifteen years as a CFO at listed biopharmaceutical companies.

Portfolio Pulse from

November 18, 2024 | 10:15 am

Sandoz has received European Commission approval for Afqlir® (aflibercept), a biosimilar to Eylea®, to treat retinal diseases. This strengthens Sandoz's biosimilar portfolio and reinforces its leadership in the global and European markets.

Portfolio Pulse from

November 15, 2024 | 6:15 am

Sandoz has raised its 2024 net sales growth guidance to high-single digits in constant currency, driven by strong biosimilars and generics demand. The company maintains its core EBITDA margin guidance at approximately 20%.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 6:07 am

Sandoz reported a strong third quarter with net sales of $2.6 billion, marking a 12% increase in constant currencies. The growth was driven by a 37% rise in biosimilars and accelerated generics growth in Europe.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 6:06 am

Sandoz has expanded its U.S. oncology portfolio with the FDA approval of a generic version of Paclitaxel, targeting metastatic breast cancer. This is the first FDA-approved ANDA for this medicine, and it is expected to drive near-term growth in the U.S. market.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2024 | 5:45 am

UnitedHealth Group will remove AbbVie's Humira from its preferred reimbursement lists in 2025, opting for lower-cost biosimilars. This follows similar moves by Cigna and CVS Health. Despite competition, AbbVie retains a dominant market share for Humira.

Portfolio Pulse from Vandana Singh

September 11, 2024 | 6:59 pm

Sandoz has received FDA approval for Enzeevu, a biosimilar to treat neovascular age-related macular degeneration. This approval strengthens Sandoz's ophthalmology portfolio in the U.S. and is expected to drive significant growth.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 5:44 am

Sandoz has launched Pyzchiva (ustekinumab) biosimilar across Europe to treat chronic inflammatory diseases, including plaque psoriasis, psoriatic arthritis, Crohn's disease, and pediatric plaque psoriasis. This launch strengthens Sandoz's immunology portfolio in Europe.

Portfolio Pulse from Benzinga Newsdesk

July 25, 2024 | 6:02 am

Sandoz has received European Commission approval for Wyost and Jubbonti, the first biosimilars of denosumab in Europe, for treating cancer-related bone disease and osteoporosis.

Portfolio Pulse from Benzinga Newsdesk

May 22, 2024 | 5:13 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.